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published Canadian literature. Deterministic and probabilistic sensitivity analyses 
were performed. Results: Mirabegron 50mg dominated tolterodine ER 4mg: incre-
mental cost savings were CA$118.91 (MOH perspective) and CA$140.48 (societal); and 
0.005 QALYs (MoH and societal) were gained. ICERs were robust over a wide range 
of sensitivity analyses, but were most sensitive to micturition symptom levels for 
tolterodine and to costs of subsequent therapy. ConClusions: Treatment with 
mirabegron 50mg is cost-effective compared with tolterodine ER 4mg in a population 
previously treated for OAB from Canadian health care and societal perspectives.
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objeCtives: The prevalence of prostate cancer in the Chinese population with 
abnormal prostate-specific antigen (PSA) levels of 4.0-10.0 ng/ml is low. The diag-
nosis can only rely on transrectal ultrasound-guided prostate biopsies (TRUS-Bx) 
which may cause major complications. We assess the cost-effectiveness of two 
diagnostic strategies for prostate cancer detection in Chinese men with abnormal 
PSA levels of 4.0-10.0 ng/ml and normal digital rectal examination of prostate 
(DRE). Methods: Using a decision tree model, we performed a cost-effectiveness 
analysis to compare the two strategies: 1) direct prostate biopsies (TRUS-Bx) and 
2) percent free PSA testing prior to TRUS-Bx. A systematic review of 855 patients 
with PSA levels of 4.0-10.0 ng/ml and normal DRE enrolled in a single medical 
institute from Jan 2002 to December 2005 was conducted. The outcome measures 
were the incremental cost-effectiveness ratio, and costs were calculated through 
activity-accumulation costing based on National Insurance Scheme Bill Size. A 
one-way sensitivity analysis was undertaken. The effectiveness was measured by 
means of the number of detected cases and actual cases (detected cases minus 
lost cases). A threshold analysis is used to illustrate the value of a given variable 
of which the two strategies have equal outcomes or costs. Results: The strat-
egy of percent free PSA with TRUS-Bx was dominant and found to be the most 
cost-effective. The incremental cost-effectiveness ratio for free PSA + TRUS-Bx 
compared with TRUS-Bx was USD 3,871.58. Strategy 2 (TRUS-Bx) would be more 
cost-effective if the cost of percent free PSA increased to USD 36.78 or if prostate 
cancer prevalence increased to 42%. ConClusions: The use of percent free PSA 
prior to TRUS-Bx is the most cost-effective diagnostic strategy and will become 
more cost-effective as prostate cancer prevalence increases in the ageing popula-
tion and the free PSA test costs down.
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objeCtives: To evaluate the cost-effectiveness of extracorporeal lithotripsy against 
ureteroscopic laser in the treatment of ureteral stones in the La Fe Hospital in 
Valencia. Methods: A decision tree was performed to evaluate the costs and 
effectiveness of two treatment strategies (starting with ESWL and second line URS, 
versus directly start with URS). It was considered as a parameter of effectiveness, 
the ratio of patient with stone-free status or the presence of insignificant residual 
fragments (< 3 mm) at 3 month of follow up. Subsequently, to consolidate the results 
of the decision tree, a sensitivity analysis of Monte Carlo with 1000 iterations was 
developed. Were available from a database of 162 patients treated for ureteral stones 
at the Hospital La Fe de Valencia. Of these, 77 were treated in lithotripsy sessions 
(27 % of whom had upper stones 1 cm), while 85 were referred directly to URS (the 
percentage of these patients with upper stones centimeter was 32.4 %). The unit 
cost of each treatment was calculated from data provided by the economic manage-
ment Department of Hospital La Fe and were 286.06 for each session in the case of 
ESWL and 1409.89 for URS. Results: The overall effectiveness after four sessions 
of lithotripsy plus second line URS was 99,76%, while in the case of URS was 98.81%. 
The average cost of ESWL plus URS alternative was 881.59 euros, while in the case 
of the strategy of starting with URS was 1,496 euros. Therefore, the ESWL plus URS 
showed dominant versus first line URS. For both group upper and less than 1 cm also 
ESWL plus URS was dominant. ConClusions: Thus, the combination of first line 
lithotripsy plus second line ureteroscopic laser is better than first line ureteroscopic 
laser for treatment of ureteral calculi in terms of in terms of cost effectiveness.
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objeCtives: To perform a cost-effectiveness analysis of Mycophenolate Sodium 
(MPS) vs Mycophenolate Mofetil (MMF) with empirical treatment of rejection, both 
options available at IMSS*. Methods: A Decision Model was designed to analyze 
effectiveness and treatment cost of MPS and MMF for renal transplant patients. 
The outcome was renal graft survival related to gastrointestinal tolerance in the 
first year. The model starts with a renal transplant performed, in a period of three 
months the patient may experience gastric intolerance or tolerance. For the patients 
showing gastric intolerance, there are two alternatives: switching to azathioprine 
or reducing the dose of mycophenolates (MPS or MMF). Then, the patient moves to 
the next state which may be rejection (humoral or cellular) or not. The absorbent 
state is the graft losses which include the cost of the intervention of renal trans-
plant plus the cost of replacement therapy: Ambulatory Peritoneal Dialysis (APD), 
Intermittent Peritoneal Mechanical Dialysis (IPMED), Intermittent Peritoneal Manual 
Dialysis (IPMAD) and Hemodialysis. A probabilistic sensitivity analysis (PSA) was 
objeCtives: Conduct an economic evaluation of darbepoetin alfa for the treatment 
of anaemia due to chronic kidney disease (CKD) compared to other erythropoiesis 
stimulating agents (ESAs) in patients on haemodialysis (HD) or peritoneal dialysis 
(PD) in Greece. Methods: A decision tree model was developed to compare overall 
costs per patient in control of darbepoetin alfa to other ESAs under different hae-
moglobin (Hb) concentrations and CKD patients. It estimates the economic impact 
of treating CKD patients on dialysis with darbepoetin alfa, originator and biosimi-
lar short-acting ESAs and pegylated epoetin beta to different Hb target strategies, 
10 (±1) g/dL and 11 (±1) g/dL, over 1 year. The effectiveness of “% patients under 
anaemia control” was defined as the number of patients being alive, not hospital-
ized, nor transfused during the analysis period. Clinical inputs depend on Hb target 
strategy and not on ESAs as extracted from published studies. Cost inputs are drug 
acquisition, administration and clinical event costs, the last comprising hospi-
talisation and blood transfusion costs (2014). Analysis was conducted from public 
third-party-payer perspective. Results: For both Hb target strategies in patients 
on HD or PD, darbepoetin alfa demonstrated the lowest overall costs per patient in 
control followed by short-acting originator ESAs, whereas pegylated epoetin beta 
and short-acting biosimilar ESAs showed the highest overall costs per patient in 
control. As clinical event costs are identical across all ESAs, the overall costs per 
patient in control are mainly affected by drug acquisition costs and by ESAs doses. 
Treatment with darbepoetin alfa at Hb target 11 (±1) g/dL is associated with the 
lowest overall costs per patient in control at € 8,210 and € 6,689, for patients on HD 
or PD, respectively. ConClusions: Darbepoetin alfa may be the most cost sav-
ing treatment compared to other ESAs for the management of anaemia (CKD) in 
patients on HD or PD in Greece.
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objeCtives: To evaluate the cost effectiveness of solifenacin 5mg compared with 
other oral antimuscarinic agents in adults with OAB from a UK NHS payer perspec-
tive. Methods: A Markov model was developed to model major symptoms of OAB 
and the efficacy and tolerability of antimuscarinics. A 5-year time-horizon with 
monthly cycles was used in the base case. Five levels of symptom severity were 
used for micturitions and incontinence (total: 25 health states). Treatment with at 
least two antimuscarinic agents was assumed before patients received botulinum 
toxin. For each antimuscarinic, there was a probability of continuing or discon-
tinuing medication, or switching to an alternative antimuscarinic with or without 
adverse events. Efficacy and tolerability inputs were based on a phase 3 study of 
solifenacin (Chapple et al. BJU Int 2004; 93: 303–10) and a mixed treatment com-
parison (results reported separately). Other model inputs were determined from the 
literature or expert opinion. All costs were based on GBP 2012/2013. Utilities were 
based on EuroQol-5D. Incremental cost-effectiveness ratios (ICER) were expressed 
as cost/quality-adjusted life year (QALY). Deterministic (DSA) and probabilistic 
(PSA) sensitivity analyses were performed. Results: Solifenacin 5mg was domi-
nant versus tolterodine extended-release 4mg, darifenacin 7.5mg, fesoterodine 4mg 
and solifenacin 10mg, and cost-effective versus darifenacin 15mg (ICER= £982.89/
QALY), fesoterodine 8mg (ICER= £232.53/QALY), oxybutynin extended-release 10mg 
(ICER= £1117.32/QALY) and trospium 60mg (ICER= £3674.25/QALY). Both DSA and PSA 
showed that results were robust at a willingness-to-pay threshold of £20,000/QALY. 
At a cost-effectiveness threshold of £20,000/QALY, the probabilities that solifena-
cin 5mg was cost-effective versus comparators were: 95.4% (tolterodine extended-
release 4mg), 92.1% (solifenacin 10mg), 97.3% (fesoterodine 4mg), 99.6% (fesoterodine 
8mg), 99.4% (oxybutynin extended-release 10mg), 99.4% (darifenacin 7.5mg), 99.2% 
(darifenacin 15mg), and 97.3% (trospium 60mg). ConClusions: Solifenacin 5mg 
appears to be a cost-effective strategy compared with other oral antimuscarinic 
agents for the treatment of adults with OAB from a UK NHS perspective.
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objeCtives: Mirabegron, a β 3-adrenoceptor agonist approved for the treatment of 
overactive bladder (OAB), has been shown to reduce OAB symptoms and improve 
HRQoL relative to placebo and to cause a lower incidence of dry mouth than tolter-
odine. We investigated the cost-effectiveness of mirabegron 50mg compared to 
tolterodine ER 4mg. Methods: A Markov model was developed to simulate man-
agement, symptom changes (micturitions, incontinence), and adverse events in OAB 
patients. The model predicted costs and QALYs over 1 year in a hypothetical cohort 
of Canadian patients previously treated for OAB. The analysis compared treatment 
with mirabegron 50mg to tolterodine ER 4mg, administered in a reference arm in 
the pivotal study SCORPIO and one of the antimuscarinic options most widely pre-
scribed and funded in Canada for the treatment of OAB, from both a payer (Ontario 
Ministry of Health and Long-term Care [MOH]) and societal perspective. Clinical and 
health state utility data for the model were based on the previously treated OAB 
population of SCORPIO. Transition probabilities between symptom severities were 
obtained using multinomial logistic regression models estimated from SCORPIO. 
Probabilities of discontinuation and switching therapy were derived from the litera-
ture. Resource utilisation estimates were based on clinical trial data, the literature 
and expert opinion. Unit costs were derived from official schedules for Ontario and 
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LPD from Taiwan health care payer’s perspective. Methods: A Markov was designed 
to simulate outcomes of two options in a hypothetical cohort of adult CKD patients 
with eGFR 15-29 mL/min/1.73m2: (1) Initiation of LPD plus KA, and (2) watchful-waiting 
on LPD and initiation of KA at eGFR < 15 mL/min/1.73m2. The Markov states included 
CKD stage 4 and 5, hemodialysis, and death. Total direct medical cost and quality-
adjusted life-years (QALYs) gained were calculated over a maximum period of 10 
years. Model inputs were derived from literature. Sensitivity analyses evaluated the 
impact of uncertainty in all model variables. Results: In base-case analysis, early KA 
initiation group (3.926 QALYs and USD548,191) gained higher QALYs and cost less than 
the watchful-waiting group (3.787 QALYs and USD887,608) (USD1= NTD30). Sensitivity 
analysis indicated that early KA initiation at eGFR at 17-29 mL/min/1.73m2 would 
be the preferred cost-effective option if reduction of eGFR decline associated with 
LPD plus KA was 4% or above. When KA was initiated at eGFR 15-17 mL/min/1.73m2, 
it would remain cost-effective if the reduction of eGFR decline associated with LPD 
plus KA was 13.5% or above. 10,000 Monte Carlo simulations showed early KA initia-
tion group to be less costly with higher QALY gained than watchful-waiting group by 
USD333,655 (95% CI 332,174-335,137) and 0.160 (95% CI 0.140-0.180) QALYs, respec-
tively. ConClusions: KA Initiation with LPD in CKD patients as early as eGFR 15-29 
mL/min/1.73m2 seems to be cost-effective in Taiwan.
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objeCtives: Hyperphoshatemia or elevated phosphorus in the blood is prevalent 
in patients with chronic kidney disease - mineral and bone disorder (CKD-MBD) 
and independently and significantly contributes to morbidity and mortality. The 
objective of this study is to perform cost - minimization analysis of the newly 
available medicines sevelamer carbonate (SC) and lanthanum carbonate (LC), for 
the treatment of hyperphosphatemia in CKD patients not on dialysis (CKD-ND) in 
Bulgaria. Methods: The results of the head-to-head clinical trial conducted by 
Spraque (2009) demonstrated equivalent efficacy and safety profiles between the 
two treatment options. To differentiate the cost in high dose and low dose thera-
peutic regimes was performed a cost-minimization analysis. Based on that was 
forecasted the expected cost savings for four years period. Discounting rate of 3.5% 
was applied. The robustness of the Results was tested through sensitivity analysis 
(SA) using Tornado diagram. Results: The estimated treatment cost per patient/
per year with SC and LC was 1441,75€ and 1569,50€ respectively at the low dose 
regimen (4000 mg of SC vs. 2000 mg of LC), while within the high dose regimen (6400 
mg of SC vs. 3000mg of LC) it was 2306,80€ and 2354,25€ respectively. Expected cost 
savings (discounted) for the four years period within the assumed market shares 
was between 1 348 794€ and 2 696 431€ at the low dose regimen, while at the high 
dose regimen the estimated cost savings was between 501 593€ and 1 001 532€ 
respectively. The results of SA (discounted) show that the major cost drivers in the 
treatment of hyperphosphatemia were the unit costs of SC and LC. ConClusions: 
The equal efficacy and lower cost of sevelamer carbonate than lanthanum carbon-
ate when used for treatment of hyperphosphatemia in patients with CKD -ND in 
Bulgaria should made the sevelamer carbonate a preference alternative.
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objeCtives: In a 36-month, open label RCT that involved 213 patients in stage 3-4 
nondialysis-dependent CKD (NDD-CKD) (INDEPENDENT study), sevelamer showed 
lower rates of all-cause mortality and dialysis inception vs. calcium carbonate. The 
aim of this study was to assess the cost-effectiveness of sevelamer vs. calcium car-
bonate in NDD-CKD patients with hyperphosphatemia in Spain. Methods: A 
Spanish National Health System perspective and lifetime horizon was chosen for 
the analysis. A Markov model was developed considering health states of “alive with 
NDD-CKD”, “alive with dialysis-dependent CKD”, and “dead”). All-cause mortal-
ity, dialysis inception, hospitalization (frequency and length of stay [LOS]), and drug 
dosage data were taken from the INDEPENDENT study. All-cause mortality and dialysis 
inception were extrapolated beyond 36 months using Weibull regression analysis. Local 
costs (euros, 2014) were applied to pharmaceutical, hospitalization and dialysis utiliza-
tion. Health utility data was taken from the published literature. Costs and effects were 
discounted at a rate of 3%. Results: In the base case analysis sevelamer was associ-
ated with increased survival, delay in dialysis inception, fewer hospitalizations, shorter 
LOS, 2,12 life years gained (LYG) and 1,61 quality-adjusted life years gained (QALYG) vs. 
calcium carbonate. Increased survival translated into more treatment time and dialysis 
sessions vs. calcium carbonate, resulting in an incremental cost of 33.687 € . The incre-
mental cost per LYG for sevelamer vs. calcium carbonate was 15.897 € and the incremen-
tal costs per QALY gained was 20.883 € . Sensitivity analysis showed that sevelamer was 
more effective and less costly (i.e., dominant) vs. calcium carbonate in time horizons 
< 6 years. ConClusions: The Spanish analysis showed that sevelamer is a cost-effec-
tive strategy vs. calcium carbonate for the treatment of hyperphosphatemia in patients 
with NDD-CKD, with cost-effectiveness ratios well below the accepted thresholds of 
30.000-45.000 € /QALY gained.
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performed using Monte Carlo technique. Results: Annual patient costs of MMF 
were: $7,746.75, $7,993.03, $7,694.19 and $7,939.14 USD. For MPS were: $7,673.35, 
$7,989.92, $7,605.80 and $7,920.64 USD with an incremental efficacy of 0.07 less graft 
rejection in APD, IPMED, IPMAD and hemodialysis respectively in one year horizon. 
PSA shows consistency on model results. ConClusions: MPS was a dominant 
alternative having lower costs and more effectiveness than MMF. These results 
show possibilities to achieve cost-savings and a potential clinical benefit in renal 
transplants, from the perspective of the Mexican public health system, in specific 
from IMSS. *IMSS (Mexican Institute of Social Security)
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objeCtives: Uncontrolled NDO may lead to medical sequelae, such as upper 
urinary tract complications and renal failure. Treatment choices include BSC 
(comprised of behavioural therapy and pads, alone or in combination with clean 
intermittent catheterisation, and possibly with anticholinergics), onabotulinum-
toxinA, and surgery. The study’s objective was to determine the cost-effectiveness 
of onabotulinumtoxinA 200 U vs. BSC among patients inadequately managed with 
anticholinergics in a UK setting. Methods: A Markov model was developed to 
compare onabotulinumtoxinA + BSC to BSC alone, with surgery as a downstream 
option. Efficacy and safety inputs were based on Phase 3 trials. Utility values were 
derived from a UK preference elicitation study. Costs were obtained from various 
NHS sources. Model uncertainty was examined through deterministic and proba-
bilistic sensitivity analyses. Results: The base case incremental cost-effective-
ness ratio (ICER) was £3,856, with an incremental cost of £1,692 and incremental 
benefits of 0.4387 quality-adjusted life-years (QALYs) for onabotulinumtoxinA 
+ BSC compared with BSC alone over 5 years. A lifetime horizon yielded an 
ICER of £2,739 per QALY. Univariate sensitivity analyses indicated that the main 
cost drivers are mean monthly use of catheters and treatment administration 
costs. Probabilistic sensitivity analysis suggested there would be 100% probability 
of the ICER being ≤ £10,000. ConClusions: Our analysis suggests that onabotu-
linumtoxinA + BSC is a cost-effective treatment option, compared with BSC alone 
for patients with NDO who are inadequately managed with anticholinergics in 
the UK.
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objeCtives: To assess the cost-effectiveness of botulinum toxin type A (BTXA; 
BOTOX®) 100 U in the treatment of idiopathic overactive bladder (OAB) with urinary 
incontinence (UI) among patients inadequately managed by anticholinergic therapy 
in France. Methods: A 10 year Markov model divided into 3-month cycles was 
developed to predict the long-term costs and health outcomes of BTXA + best sup-
portive care (BSC; comprising behavioural therapy, incontinence pads, continued 
anticholinergic therapy for some patients and, occasionally, catheters) versus BSC 
alone from a societal perspective (excluding productivity loss) in France. Health 
states were determined by daily number of UI episodes. Patients discontinuing BTXA 
and a proportion of patients receiving BSC alone were eligible to receive downstream 
sacral nerve stimulation (SNS). Costs and health outcomes were discounted at 4% 
annually. The modelled cohort comprised patients from two phase 3 clinical trials of 
BTXA and a long-term extension study. Literature, published guidelines and expert 
advice informed all other model assumptions. Incontinence Quality of Life (I-QOL) 
data from the trials were mapped to 5-dimension EuroQol questionnaire (EQ-5D) 
utility values using a published algorithm. Sensitivity analyses assessed the impact 
of varying model parameters as well as providing a direct comparison between BTXA 
+ BSC and SNS. Results: BTXA + BSC was economically dominant compared with 
BSC alone in the base case (quality-adjusted life-year [QALY] gain: +0.198; cost differ-
ence: –€ 1937). BTXA + BSC was also economically dominant when compared directly 
with SNS (QALY gain: +0.143; cost difference: –€ 8973). Probabilistic sensitivity analy-
sis indicated that the incremental cost-effectiveness ratio has approximately a 90% 
likelihood of being below € 20 000 per QALY gained. ConClusions: In France, BTXA 
+ BSC is economically dominant over BSC alone for patients with OAB, symptoms 
of UI and an inadequate response to anticholinergic therapy.
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objeCtives: In Taiwan, chronic kidney disease (CKD) patients with estimated glo-
merular filtration rate (eGFR) < 15 mL/min/1.73m2 are suggested to be managed with 
low-protein diet (LPD) (≤ 0.6 g/kg/day) plus ketoanalogs (KA) supplement. Recent clini-
cal findings showed early KA initiation with LPD at eGFR 15-29 mL/min/1.73m2 would 
significantly slow down eGFR decline. We compared cost-effectiveness of KA initiation 
at eGFR 15-29 mL/min/1.73m2 versus eGFR < 15 mL/min/1.73m2 in CKD patients on 
